1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Kisunla |
| structure | File | |
| classes | List of String, delimiter: , | Anti-amyloid beta (Aβ) monoclonal antibody • targets pyroglutamated Aβ in plaques |
| mechanism | String | |
| uses | String | Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 |
| starting_dose | String | 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance |
| preparations | String | 350 mg/20 mL vial for IV infusion |
| fda_max | String | 1400 mg q4w |
| pill_id | Text | |
| routes | List of String, delimiter: , | IV infusion every 4 weeks |
| onset | String | Amyloid PET clearance within months; cognitive benefit over 18 months |
| duration | String | Treatment can be discontinued upon achieving amyloid clearance |
| halflife | String | ~12.1 days |
| bioavailability | String | 100% (IV) |
| pregnancy | String | Limited data |
| legal | String | Rx; ARIA monitoring required |
